Stevanato Group Announces Change in Ex-Dividend Date for its Dividend

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, June 7, 2023
Information
Tags: 
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, New York Stock Exchange, EUR, NYSE, Pharmaceutical industry
Geotags: 
EUROPE, UNITED STATES, ITALY, NORTH AMERICA, ILLINOIS
⚠ partially generated by AI ↴
Organisation: 
STEVANATO GROUP, STEVANATO GROUP S.P.A.
Stock Symbol: 
NYSE:STVN
Summary
Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules.
  • The new ex-dividend date for the dividend will be June 7, 2023, and the record date remains June 6, 2023.
  • The dividend will continue to be payable on July 17, 2023.


Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules. The new ex-dividend date for the dividend will be June 7, 2023, and the record date remains June 6, 2023. The dividend will continue to be payable on July 17, 2023.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

For more information, please visit www.stevanatogroup.com.

Copyright: 
Copyright Business Wire 2023